Boehringer Ingelheim reveals new Phase III data on Tiotropium in asthma patients

Boehringer Ingelheim has revealed new Phase III data on tiotropium, which showed that the drug candidate improves lung function in adult patients with mild, moderate and severe asthma irrespective of allergic status.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news